The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > BUSINESS
BUSINESS
- Janssen, Taiho to Copromote Psoriasis Med Guselkumab
December 19, 2017
- Kyowa Kirin’s Burosumab Gains European Panel Backing for Conditional Approval
December 19, 2017
- Pfizer, Takeda to End Xeljanz Distribution/Copromotion Scheme
December 19, 2017
- Takeda/TiGenix Cell Therapy for Crohn’s Disease Complication Gets European Panel Nod
December 19, 2017
- Authorized Generic Makers Thrive in April-September, but Pricing Overhaul Casts Cloud on Their Outlook
December 18, 2017
- Sawai Wins Supreme Court Victory in Elplat Patent Suit
December 18, 2017
- Pfizer’s Ibrance Now Available in Japan
December 18, 2017
- Ethical Drug Sales Up 6.4% in October on Keytruda/SGLT-2 Boost: Crecon
December 18, 2017
- 1st Sakigake-Designated Product Earns Approval
December 18, 2017
- Ono Out-Licenses New I/O Candidate to Bristol-Myers
December 15, 2017
- New Pfizer Japan Chief Resolved to Grow Industry and Contribute to Society
December 15, 2017
- Chugai to Appoint COO Kosaka as CEO, with Nagayama Continuing to Serve as Chairman
December 15, 2017
- JCR’s BBB-Penetrating Hunter Syndrome Drug Delivers Positive PI/II Data; PII/III Study to Start Next Year
December 15, 2017
- Partnerships Hold Key to Success, Acquisition Not Our Goal: Takeda R&D Head
December 15, 2017
- Daiichi Sankyo to Shed Non-Cancer R&D Costs, Allocate More Resources to Oncology: CEO
December 14, 2017
- Daiichi Sankyo, Puma Tie Up on HER2-Targeting Combo Therapy
December 14, 2017
- Mitsubishi Tanabe Hooks Up with 2 Japanese Startups on ALS
December 14, 2017
- Ono Links Up with Canada’s Cyclenium on Macrocycles
December 13, 2017
- Kaketsuken Announces Biz Transfer to Meiji-Kumamoto JV
December 13, 2017
- Atezolizumab-Avastin Combo Delivers Positive Data in 1st Line RCC: Chugai
December 12, 2017
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…